Fig. 3From: A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseChanges in maximum inspiratory a and expiratory b pressures, forced vital capacity c, and distance walked d. Data presented as mean changes from baseline to week 72 in subjects receiving 20Â mg/kg reveglucosidase alfa infusion every 2Â weeks. Baseline is defined as the last measurement prior to the first infusion. The error bars represent the 95% confidence interval. The statistical significance of treatment effects was not determined, as no pre-planned statistical analyses were conducted for this study. Abbreviations: FVC, forced vital capacity; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressureBack to article page